Follow
Tumor Markers
Tumor Marker: a biomarker found in the body system that can be elevated by the presence of all types of cancer. Each tumor marker is indicative of a particular disease process, and are used in oncology to help detect the presence of cancer.
MAY 11, 2015 | 1:00 PM
Extracellular vesicles (EVs) include the exosomes (30-100 nm) that are produced through the endocytic pathway via the multivesicular bodies and the ectosomes (100-1000 nm) that are released t...
OCT 30, 2014 | 12:00 PM
It has become widely accepted that the presence of intraepithelial CD8+ T cell correlate with improved patient survival. In contrast, tumors largely devoid of immune infiltrations or infiltra...
OCT 30, 2014 | 7:30 AM
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
OCT 29, 2014 | 1:30 PM
Human malignant glioma is a uniformly fatal disease, causing over 14,000 deaths in the US this year. Adults diagnosed with malignant brain tumors have a median survival of approximately 15 mo...
SEP 10, 2014 | 10:00 AM
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
FEB 05, 2014 | 2:00 PM
C.E. CREDITS
It is increasingly recognized that the genetic background (i.e., all genomic sequences other than the gene(s) of interest) can have profound influences on the phenotype of an animal model. I...
OCT 17, 2013 | 12:00 PM
The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spit...
OCT 17, 2013 | 9:00 AM
C.E. CREDITS
Cancer metastases develop when tumor cells known as circulating tumor cells (CTCs) are shed from a tumor, circulate through the blood stream and colonize a distant tissue. The number of CTCs...
OCT 16, 2013 | 2:00 PM
C.E. CREDITS
While the Prostate Specific Antigen (PSA) blood test has been available since 1986 and FDA-approved for the early detection of prostate cancer since the early 1990s, 2012 marked a critical in...
OCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...
SEP 10, 2014 | 10:00 AM
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
FEB 05, 2014 | 2:00 PM
C.E. CREDITS
It is increasingly recognized that the genetic background (i.e., all genomic sequences other than the gene(s) of interest) can have profound influences on the phenotype of an animal model. I...
OCT 17, 2013 | 12:00 PM
The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spit...
OCT 17, 2013 | 9:00 AM
C.E. CREDITS
Cancer metastases develop when tumor cells known as circulating tumor cells (CTCs) are shed from a tumor, circulate through the blood stream and colonize a distant tissue. The number of CTCs...
OCT 16, 2013 | 2:00 PM
C.E. CREDITS
While the Prostate Specific Antigen (PSA) blood test has been available since 1986 and FDA-approved for the early detection of prostate cancer since the early 1990s, 2012 marked a critical in...
OCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...